Leproust Emily M. sold $14.2M of TWST
Leproust Emily M. (Chief Executive Officer) sold 113,318 shares of Twist Bioscience Corp (TWST) at $125.16 ($14.18M total) on 2026-08-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the CEO’s disclosed sale size, price, and post-transaction holdings, which may affect short-term sentiment but does not change fundamentals based on the provided text.
Market read
Traders may briefly reassess sentiment around TWST due to the CEO’s sale, but the 10b5-1 framing typically reduces interpretive weight.
What to watch
The article provides no context on total compensation, tax-motivated selling, or whether the sale schedule is part of a recurring pattern, which can make the signal weaker than it appears.
Background
The article is an SEC Form 4 insider transaction disclosure for Twist Bioscience.
Ticker impact
Twist Bioscience CEO Emily M. Leproust filed a Form 4 selling 113,318 shares at $125.1615 on 2026-08-10 under a 10b5-1 plan.
Likely limited near-term impact; any reaction is typically sentiment-driven and can fade as 10b5-1 context is known.
The filing is a routine Form 4 transaction with stated 10b5-1 pre-arrangement, and it does not include new guidance, results, or regulatory/contract developments.
Market effects
No clear sector read-through from a single CEO 10b5-1 sale.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, unusually large insider sales can still be interpreted by some traders as reduced confidence, especially if coinciding with other negative signals not mentioned here.
Key entities
- issuerTwist Bioscience Corp
Subject of the Form 4 insider transaction disclosure.
- insiderEmily M. Leproust
CEO and officer/director who sold shares under a pre-arranged 10b5-1 plan.
